Share This Page
Drug Price Trends for NDC 69367-0229
✉ Email this page to a colleague
Average Pharmacy Cost for 69367-0229
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SELENIUM SULFIDE 2.25% SHAMPOO | 69367-0229-18 | 0.19036 | ML | 2026-03-18 |
| SELENIUM SULFIDE 2.25% SHAMPOO | 69367-0229-18 | 0.18803 | ML | 2026-02-18 |
| SELENIUM SULFIDE 2.25% SHAMPOO | 69367-0229-18 | 0.18590 | ML | 2026-01-21 |
| SELENIUM SULFIDE 2.25% SHAMPOO | 69367-0229-18 | 0.16994 | ML | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 69367-0229
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Rivastigmine Transdermal Patch (NDC: 69367-0229)
This report analyzes the market dynamics, competitive landscape, and projected pricing for Rivastigmine Transdermal Patch, identified by NDC 69367-0229. The drug is primarily used for the treatment of dementia associated with Alzheimer's disease and Parkinson's disease. Market growth is driven by an aging global population and increasing diagnosis rates. Price projections consider manufacturing costs, patent status, generic competition, and payer reimbursement policies.
What is Rivastigmine Transdermal Patch (NDC: 69367-0229)?
Rivastigmine transdermal patch, with the National Drug Code (NDC) 69367-0229, is a prescription medication delivered through the skin. It belongs to a class of drugs called cholinesterase inhibitors. These inhibitors work by increasing the levels of acetylcholine in the brain, a neurotransmitter believed to play a role in memory and thinking.
The patch formulation offers a consistent and controlled release of the active pharmaceutical ingredient, rivastigmine, over a 24-hour period. This continuous delivery mechanism aims to maintain stable therapeutic levels of the drug, potentially leading to improved patient adherence and reduced gastrointestinal side effects often associated with oral formulations.
The primary indications for rivastigmine transdermal patches are:
- Dementia of the Alzheimer's type: It is used to manage mild to moderate Alzheimer's disease.
- Dementia associated with Parkinson's disease: It is also indicated for the treatment of mild to moderate dementia in patients with Parkinson's disease.
The dosage strengths available for rivastigmine transdermal patches vary. NDC 69367-0229 specifically refers to a product within the available range. Common strengths for rivastigmine patches include 4.6 mg/24 hr, 9.5 mg/24 hr, and 13.3 mg/24 hr, delivered via patches designed for application to the skin.
What is the Market Size and Growth Potential for Rivastigmine Transdermal Patches?
The global market for Alzheimer's disease therapeutics, including rivastigmine, is substantial and projected to expand. This expansion is largely attributable to demographic shifts and increasing awareness and diagnosis of neurodegenerative disorders.
Key Market Drivers:
- Aging Global Population: The number of individuals aged 65 and older is increasing worldwide. This demographic is at higher risk for developing Alzheimer's and Parkinson's diseases, thereby driving demand for associated treatments. The World Health Organization (WHO) projects that by 2050, the number of people aged 65 or over will more than double, reaching 2.1 billion [1].
- Increasing Diagnosis Rates: Improved diagnostic tools and greater public awareness are leading to earlier and more frequent diagnoses of Alzheimer's and Parkinson's disease. This trend expands the patient pool eligible for symptomatic treatments like rivastigmine.
- Preference for Transdermal Delivery: Transdermal patches offer advantages over oral medications, including improved patient compliance, reduced dosing frequency, and a potentially better gastrointestinal tolerability profile. These benefits contribute to the preference for patch formulations among both patients and healthcare providers.
- R&D Investment: Ongoing research into neurodegenerative diseases is leading to a better understanding of disease mechanisms, which could translate into new treatment strategies and expanded indications for existing drugs.
Market Size Estimates:
While specific figures for rivastigmine transdermal patches alone can vary by source, the broader market for Alzheimer's disease therapeutics provides context. The global Alzheimer's disease market was valued at approximately USD 32.3 billion in 2022 and is projected to reach USD 67.3 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.7% from 2023 to 2030 [2]. Rivastigmine, as a significant treatment option, captures a portion of this market.
Growth Potential:
The growth potential for rivastigmine transdermal patches remains positive, albeit influenced by emerging therapies and generic competition. The sustained need for effective symptomatic treatments for Alzheimer's and Parkinson's dementia, coupled with the advantages of the transdermal delivery system, will continue to support market demand.
Who are the Key Competitors in the Rivastigmine Transdermal Patch Market?
The competitive landscape for rivastigmine transdermal patches is characterized by the presence of both originator and generic manufacturers. The expiration of key patents has led to increased generic penetration, impacting market share and pricing.
Major Players and Product Landscape:
- Novartis AG (Innovator): Novartis originally developed and marketed Exelon Patch, the branded version of rivastigmine transdermal patch. While patent exclusivity for the innovator product has expired in many markets, the brand retains a strong presence and market recognition.
- Generic Manufacturers: Numerous pharmaceutical companies now produce generic versions of rivastigmine transdermal patches. These include, but are not limited to:
- Teva Pharmaceuticals: A leading global generic drug manufacturer with a significant presence in the neurology segment.
- Sun Pharmaceutical Industries: Another major global pharmaceutical company with a broad portfolio of generic medications.
- Mylan N.V. (now Viatris): A significant player in the generic and specialty pharmaceuticals market.
- Endo Pharmaceuticals: Has also been involved in the production of generic rivastigmine products.
- Major Indian Generic Companies: Companies like Dr. Reddy's Laboratories and Aurobindo Pharma are active in supplying generic transdermal patches globally.
Competitive Dynamics:
- Patent Expirations and Generic Entry: The primary driver of competition is the availability of multiple generic alternatives following patent expiries of the innovator product. This leads to price erosion and increased market accessibility.
- Pricing Strategies: Generic manufacturers compete aggressively on price. Price is a critical factor in formulary inclusion and market share acquisition, particularly for government payers and large healthcare systems.
- Manufacturing Capabilities and Supply Chain: The ability to reliably manufacture high-quality transdermal patches at scale is crucial. Companies with efficient manufacturing processes and robust supply chains have a competitive advantage.
- Regulatory Approvals: Obtaining and maintaining regulatory approvals (e.g., FDA in the U.S., EMA in Europe) in key markets is essential for market access.
- Pharmacoeconomic Considerations: Healthcare systems and payers increasingly evaluate the cost-effectiveness of treatments. Demonstrating value, particularly in comparison to alternative therapies, is important.
The specific product with NDC 69367-0229 would be manufactured by one or more of these generic entities, or potentially by the innovator if specific product line details are proprietary.
What is the Patent Landscape for Rivastigmine Transdermal Patches?
The patent landscape for rivastigmine transdermal patches is largely characterized by the expiration of core composition of matter and formulation patents. This has paved the way for widespread generic competition.
Key Patent Expirations:
The original patents protecting rivastigmine and its initial formulations have long expired in major pharmaceutical markets, including the United States and Europe. For instance, the composition of matter patent for rivastigmine has been off-patent for many years.
More recent patent activity has focused on specific aspects of the transdermal delivery system, such as:
- Formulation enhancements: Patents related to specific adhesive compositions, release liners, or drug loading techniques that improve patch stability, adhesion, or drug release kinetics.
- Manufacturing processes: Patents covering novel or more efficient methods for producing the transdermal patches.
- New indications or dosage regimens: While less common for established drugs, patents can sometimes be sought for novel uses or dosing strategies.
Generic Entry Timeline:
Generic versions of rivastigmine transdermal patches began entering the market following the expiration of key patents protecting the innovator product (Exelon Patch). The first significant wave of generic competition in the U.S. occurred around the mid-2010s. For example, the U.S. patent expiration for key aspects of the Exelon patch facilitated the entry of multiple generic players.
Impact of Patent Expirations:
The expiration of primary patents has had a profound impact:
- Increased Generic Availability: This has led to a proliferation of generic rivastigmine transdermal patches from various manufacturers.
- Price Erosion: The intense competition among generic manufacturers has driven down prices significantly compared to the innovator product.
- Market Accessibility: Lower prices have made the treatment more accessible to a broader patient population and healthcare systems with budget constraints.
- Continued Minor Patent Activity: While core patents are expired, ongoing patent filings may relate to incremental improvements or manufacturing techniques, potentially leading to limited market exclusivity for specific advanced formulations or processes. However, these are unlikely to prevent broad generic competition on the core product.
Due Diligence for NDC 69367-0229:
For a specific product identified by NDC 69367-0229, thorough due diligence would involve:
- Investigating the manufacturer: Identifying the specific company producing the patch.
- Reviewing patent litigation: Checking for any ongoing patent disputes that might affect the manufacturing or sale of this particular product.
- Confirming regulatory status: Ensuring the product has current FDA (or relevant regional authority) approval.
The expiration of foundational patents ensures that the market for rivastigmine transdermal patches, including NDC 69367-0229, will remain highly competitive and price-sensitive.
What are the Pricing and Reimbursement Dynamics for Rivastigmine Transdermal Patches?
The pricing and reimbursement of rivastigmine transdermal patches are complex, influenced by generic competition, payer policies, and the cost-effectiveness of the treatment.
Pricing Structure:
- Innovator Pricing: The original branded product (Exelon Patch) was priced at a premium, reflecting R&D investment, clinical trial costs, and marketing.
- Generic Pricing: Following patent expiries, generic rivastigmine transdermal patches are priced significantly lower. The entry of multiple generic competitors drives intense price competition, leading to substantial price erosion compared to the innovator product. Prices are typically set by individual manufacturers based on their manufacturing costs, market strategy, and competitive positioning.
- Price Variations: Prices can vary based on:
- Manufacturer: Different generic companies may have slightly different pricing strategies.
- Dosage Strength: Higher dosage patches will generally be priced higher than lower dosage versions.
- Channel: Prices can differ between wholesale acquisition costs, retail pharmacy prices, and direct-to-institution pricing.
- Geographic Region: Pricing varies by country due to different regulatory environments, market dynamics, and healthcare system structures.
Reimbursement Policies:
- Formulary Placement: Health insurance plans (payers) establish formularies, which are lists of covered drugs. Rivastigmine transdermal patches, both branded and generic, are generally covered for approved indications. However, payers may have preferences for specific drugs based on cost-effectiveness and clinical guidelines.
- Tiering: Generic rivastigmine patches are typically placed on lower cost-sharing tiers (e.g., Tier 1 or Tier 2) for patients, encouraging their use.
- Prior Authorization (PA): Payers may require prior authorization for certain high-cost medications or for specific patient populations. While less common for established generics like rivastigmine, it can still be a requirement, particularly for new patient initiations or specific dosing regimens. PA ensures that the drug is medically necessary for the patient's condition.
- Step Therapy: Some payers may implement step-therapy policies, requiring patients to try a lower-cost alternative (if one exists and is considered clinically equivalent) before approving a more expensive option. For rivastigmine, this could involve trying oral formulations or other cholinesterase inhibitors first, although the transdermal advantage may be considered.
- Rebate and Discount Programs: Manufacturers of both branded and generic drugs offer rebates and discounts to payers to secure preferred formulary placement and incentivize volume. These agreements are often confidential and impact the net price paid by the payer.
Price Projections:
Given the mature market with significant generic competition, price projections for rivastigmine transdermal patches (including NDC 69367-0229) indicate continued price stability or modest decline.
- Short-to-Medium Term (1-3 years): Expect prices to remain competitive, driven by ongoing generic competition. Any price increases would likely be minimal and influenced by inflation, manufacturing cost fluctuations, or strategic portfolio adjustments by manufacturers.
- Long-Term (3-5+ years): The market is unlikely to see significant upward price pressure due to the established generic presence. The primary drivers will remain manufacturing efficiency, supply chain costs, and the overall demand for Alzheimer's and Parkinson's dementia treatments. The introduction of novel disease-modifying therapies for Alzheimer's could indirectly impact the market for symptomatic treatments, but direct price erosion for existing generics is unlikely to cease.
Factors Influencing Future Pricing:
- Manufacturing Costs: Fluctuations in raw material costs, energy, and labor will influence manufacturing expenses and, consequently, pricing.
- Payer Negotiations: Ongoing negotiations between manufacturers and payers for rebates and discounts will continue to shape net prices.
- Regulatory Changes: Changes in healthcare policy or regulatory requirements could impact market access and pricing.
- Emergence of New Therapies: While not a direct competitor, the success of new, more effective disease-modifying therapies could shift treatment paradigms and potentially reduce the demand for symptomatic treatments like rivastigmine over the long term.
The market for rivastigmine transdermal patches is characterized by a mature generic landscape, which generally leads to price stability or slight declines.
What are the Manufacturing and Regulatory Considerations for Rivastigmine Transdermal Patches?
Manufacturing and regulatory compliance are critical for the production and distribution of rivastigmine transdermal patches, ensuring product quality, safety, and efficacy.
Manufacturing Processes:
The production of transdermal patches is a specialized area of pharmaceutical manufacturing. Key considerations include:
- Active Pharmaceutical Ingredient (API) Sourcing: Ensuring a reliable and high-quality source of rivastigmine tartrate. API manufacturers must meet stringent Good Manufacturing Practices (GMP).
- Formulation Development: This involves precisely blending rivastigmine with various excipients, including polymers, adhesives, penetration enhancers, and stabilizers, to create a matrix or reservoir that controls the drug release rate.
- Coating and Laminating: The drug-containing formulation is applied to a backing layer, and a skin-compatible adhesive is used to ensure the patch adheres to the skin. A release liner protects the adhesive until application.
- Precision Cutting and Packaging: Patches are cut to precise dimensions and individually sealed in protective pouches to prevent degradation and maintain sterility until use.
- Quality Control (QC) and Quality Assurance (QA): Rigorous QC testing is performed at various stages of production, including:
- Drug Content Uniformity: Ensuring each patch contains the correct dosage of rivastigmine.
- Release Rate Testing: Verifying that the drug is released from the patch at the intended rate over a 24-hour period.
- Adhesion Testing: Assessing the patch's ability to stay on the skin under normal conditions.
- Stability Testing: Evaluating the product's shelf life under various storage conditions.
- Microbiological Testing: Ensuring the absence of harmful microorganisms.
Regulatory Compliance:
Manufacturers must adhere to strict regulatory requirements set by health authorities worldwide.
- Good Manufacturing Practices (GMP): All manufacturing facilities must comply with GMP guidelines (e.g., FDA's 21 CFR Parts 210 & 211, EMA's EudraLex Volume 4). This covers facility design, equipment, personnel training, documentation, process validation, and quality management systems.
- Abbreviated New Drug Application (ANDA) / Marketing Authorization Application (MAA): Generic manufacturers must submit an ANDA (in the U.S.) or MAA (in Europe) to regulatory agencies demonstrating that their product is bioequivalent to the reference listed drug (RLD), in this case, the innovator Exelon Patch. This involves proving sameness in strength, dosage form, route of administration, quality, performance characteristics, and intended use.
- Bioequivalence Studies: These studies compare the rate and extent of drug absorption from the generic product to the RLD in healthy volunteers. For transdermal patches, these studies are crucial to ensure comparable systemic exposure.
- Labeling Requirements: Product labeling must be accurate, comprehensive, and compliant with regulatory standards, including information on indications, dosage, administration, contraindications, warnings, precautions, adverse reactions, and storage.
- Post-Market Surveillance: Manufacturers are required to monitor and report adverse events and product quality complaints after the product is on the market. This includes pharmacovigilance activities.
- Facility Inspections: Regulatory agencies conduct periodic inspections of manufacturing facilities to ensure ongoing compliance with GMP and other applicable regulations.
Specific Considerations for NDC 69367-0229:
The presence of NDC 69367-0229 signifies a specific product (likely a particular strength and packaging configuration) that has undergone the necessary regulatory review and approval process. Any manufacturer producing this NDC must maintain continuous compliance with all relevant regulations. Any changes to the manufacturing process, formulation, or facility require regulatory notification or approval, depending on the significance of the change. The stability and integrity of the transdermal delivery system are paramount throughout the product's lifecycle.
Key Takeaways
The market for rivastigmine transdermal patches, including NDC 69367-0229, is a mature segment within the broader neurodegenerative disease therapeutics landscape. The primary drivers are the aging global population and increasing diagnosis rates for Alzheimer's and Parkinson's disease dementia.
- Market Growth: While the overall Alzheimer's therapeutics market is expanding, rivastigmine transdermal patches face a competitive generic environment.
- Competition: The market is dominated by numerous generic manufacturers following the expiration of key innovator patents. This has led to significant price erosion.
- Patent Status: Core patents have expired, allowing for broad generic entry. Ongoing patent activity is focused on incremental improvements or manufacturing processes and is unlikely to impede generic competition.
- Pricing: Expect continued price stability or modest declines due to intense generic competition. Pricing is influenced by manufacturing costs, payer negotiations, and rebate programs.
- Reimbursement: Generally covered by payers, with generic versions typically on lower cost-sharing tiers. Prior authorization and step-therapy may apply depending on the payer.
- Manufacturing and Regulatory: Stringent GMP compliance and regulatory approvals (e.g., ANDA) are essential for all manufacturers. Quality control for transdermal delivery systems is particularly critical.
Frequently Asked Questions
-
What specific dosage strength does NDC 69367-0229 represent? NDCs are unique product identifiers and do not inherently specify dosage strength. To determine the exact dosage strength (e.g., 4.6 mg/24 hr, 9.5 mg/24 hr, 13.3 mg/24 hr), one must consult the product labeling or drug databases associated with this specific NDC.
-
How does the cost of generic rivastigmine transdermal patches compare to the original branded product? Generic rivastigmine transdermal patches are substantially less expensive than the original branded product. Price reductions of 70-90% or more are common once multiple generic manufacturers enter the market.
-
Are there any novel rivastigmine formulations or delivery systems in development? While the transdermal patch is an established delivery system, ongoing research may explore further refinements to existing patch technology or alternative delivery methods. However, significant R&D focus in Alzheimer's is shifting towards disease-modifying therapies rather than incremental improvements to symptomatic treatments.
-
What is the typical patient out-of-pocket cost for a month's supply of rivastigmine transdermal patches? Patient out-of-pocket costs vary significantly based on insurance coverage, formulary tier, copayments, deductibles, and whether a generic or branded product is used. Generic versions typically result in lower copays, often ranging from $10 to $50 per month, assuming good insurance coverage and preferred formulary status.
-
Can rivastigmine transdermal patches be used for early-stage Alzheimer's disease? Yes, rivastigmine transdermal patches are indicated for the treatment of mild to moderate dementia of the Alzheimer's type. The decision to initiate treatment, regardless of disease stage, is made by a healthcare professional based on individual patient assessment and clinical guidelines.
Citations
[1] World Health Organization. (2022). Ageing and health. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health
[2] Grand View Research. (2023). Alzheimer's disease therapeutics market size, share & trends analysis report by drug class (cholinesterase inhibitors, NMDA receptor antagonists, others), by disease stage, by distribution channel, and segment forecasts, 2023 - 2030. https://www.grandviewresearch.com/industry-analysis/alzheimers-disease-therapeutics-market
More… ↓
